Association of prebiotic/probiotic intake with MASLD: evidence from NHANES and randomized controlled trials in the context of prediction, prevention, and a personalized medicine framework

Lekakis V, Papatheodoridis GV. Natural history of metabolic dysfunction-associated steatotic liver disease. Eur J Intern Med. 2024;122:3–10. https://doi.org/10.1016/j.ejim.2023.11.005[publishedOnlineFirst:2023/11/09] .

Article  CAS  PubMed  Google Scholar 

Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Translat Gastroenterol Hepatol 2020;5:16. https://doi.org/10.21037/tgh.2019.09.08[publishedOnlineFirst:2020/04/08] .

Article  PubMed  PubMed Central  Google Scholar 

Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology (Baltimore, MD). 2023;77(4):1335–47. https://doi.org/10.1097/hep.0000000000000004[publishedOnlineFirst:2023/01/11] .

Article  PubMed  Google Scholar 

Mann JP, Valenti l, scorletti e, et al. nonalcoholic fatty liver disease in children. Sem Liver Disease 2018;38(1):1–13. https://doi.org/10.1055/s-0038-1627456 [published Online First: 2018/02/23]

Le MH, Yeo YH, Zou B, et al. Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach. Clin Mol Hepatol. 2022;28(4):841–50. https://doi.org/10.3350/cmh.2022.0239[publishedOnlineFirst:2022/09/20] .

Article  PubMed  PubMed Central  Google Scholar 

Hosseini Shabanan S, Martins VF, Wolfson T, et al. MASLD: what we have learned and where we need to go-a call to action. Radiographics : Rev Publ Radiological Soc North Am, Inc 2024;44(11):e240048. https://doi.org/10.1148/rg.240048 [published Online First: 2024/10/18]

Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2021;18(4):223–38. https://doi.org/10.1038/s41575-020-00381-6[publishedOnlineFirst:2020/12/23] .

Article  PubMed  Google Scholar 

Barone M, Martucci M, Sciara G, et al. Towards a personalized prediction, prevention and therapy of insomnia: gut microbiota profile can discriminate between paradoxical and objective insomnia in post-menopausal women. EPMA J. 2024;15(3):471–89. https://doi.org/10.1007/s13167-024-00369-1[publishedOnlineFirst:2024/09/06] .

Article  PubMed  PubMed Central  Google Scholar 

Ratziu V, Friedman SL. Why do so many nonalcoholic steatohepatitis trials fail? Gastroenterology. 2023;165(1):5–10. https://doi.org/10.1053/j.gastro.2020.05.046[publishedOnlineFirst:2020/05/23] .

Article  PubMed  Google Scholar 

Kobayashi T, Iwaki M, Nakajima A, et al. Current research on the pathogenesis of NAFLD/NASH and the gut-liver axis: gut microbiota, dysbiosis, and leaky-gut syndrome. Int J Mol Sci 2022;23(19) https://doi.org/10.3390/ijms231911689 [published Online First: 2022/10/15]

Alisi A, McCaughan G, Grønbæk H. Role of gut microbiota and immune cells in metabolic-associated fatty liver disease: clinical impact. Hep Intl 2024;18(Suppl 2):861–72. https://doi.org/10.1007/s12072-024-10674-6[publishedOnlineFirst:2024/07/12] .

Article  Google Scholar 

Wang H, Guo Y, Han W, et al. Tauroursodeoxycholic acid improves nonalcoholic fatty liver disease by regulating gut microbiota and bile acid metabolism. J Agric Food Chem 2024;72(36):20194–210. https://doi.org/10.1021/acs.jafc.4c04630[publishedOnlineFirst:2024/08/28] .

Article  CAS  PubMed  Google Scholar 

Ross FC, Patangia D, Grimaud G, et al. The interplay between diet and the gut microbiome: implications for health and disease. Nat Rev Microbiol 2024;22(11):671–86. https://doi.org/10.1038/s41579-024-01068-4[publishedOnlineFirst:2024/07/16] .

Article  CAS  PubMed  Google Scholar 

Segata N. Gut microbiome: westernization and the disappearance of intestinal diversity. Curr Biol : CB 2015;25(14):R611–3. https://doi.org/10.1016/j.cub.2015.05.040[publishedOnlineFirst:2015/07/22] .

Article  CAS  PubMed  Google Scholar 

Van Hul M, Cani PD, Petitfils C, et al. What defines a healthy gut microbiome? Gut 2024;73(11):1893–908. https://doi.org/10.1136/gutjnl-2024-333378[publishedOnlineFirst:2024/09/26] .

Article  CAS  PubMed  Google Scholar 

Luther J, Garber JJ, Khalili H, et al. Hepatic injury in nonalcoholic steatohepatitis contributes to altered intestinal permeability. Cell Mol Gastroenterol Hepatol 2015;1(2):222–32. https://doi.org/10.1016/j.jcmgh.2015.01.001[publishedOnlineFirst:2015/09/26] .

Article  PubMed  PubMed Central  Google Scholar 

Saeed H, Díaz LA, Gil-Gómez A, et al. Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol 2024. https://doi.org/10.3350/cmh.2024.0811[publishedOnlineFirst:2024/11/28] .

Article  PubMed  Google Scholar 

Kolodziejczyk AA, Zheng D, Shibolet O, et al. The role of the microbiome in NAFLD and NASH. EMBO Mol Med 2019;11(2) https://doi.org/10.15252/emmm.201809302 [published Online First: 2018/12/29]

Basil B, Myke-Mbata BK, Eze OE, et al. From adiposity to steatosis: metabolic dysfunction-associated steatotic liver disease, a hepatic expression of metabolic syndrome - current insights and future directions. Clin Diabetes Endocrinol 2024;10(1):39. https://doi.org/10.1186/s40842-024-00187-4[publishedOnlineFirst:2024/12/02] .

Article  PubMed  PubMed Central  Google Scholar 

Gäbele E, Dostert K, Hofmann C, et al. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J Hepatol 2011;55(6):1391–9. https://doi.org/10.1016/j.jhep.2011.02.035[publishedOnlineFirst:2011/06/28] .

Article  CAS  PubMed  Google Scholar 

Rahman K, Desai C, Iyer SS, et al. Loss of junctional adhesion molecule A promotes severe steatohepatitis in mice on a diet high in saturated fat, fructose, and cholesterol. Gastroenterology 2016;151(4):733-46.e12. https://doi.org/10.1053/j.gastro.2016.06.022[publishedOnlineFirst:2016/06/28] .

Article  CAS  PubMed  Google Scholar 

Negi CK, Babica P, Bajard L, et al. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metab: Clin Exp 2022;126:154925. https://doi.org/10.1016/j.metabol.2021.154925 [published Online First: 2021/11/07]

Mohamad Nor MH, Ayob N, Mokhtar NM, et al. The effect of probiotics (MCP(®) BCMC(®) Strains) on hepatic steatosis, small intestinal mucosal immune function, and intestinal barrier in patients with non-alcoholic fatty liver disease. Nutrients 2021;13(9) https://doi.org/10.3390/nu13093192 [published Online First: 2021/09/29]

Gkiourtzis Ν, Kalopitas G, Vadarlis A, et al. The benefit of probiotics in pediatric nonalcoholic fatty liver disease: a meta-analysis of randomized control trials. J Pediatr Gastroenterol Nutr 2022;75(3):e31–7. https://doi.org/10.1097/mpg.0000000000003537[publishedOnlineFirst:2022/06/28] .

Article  PubMed  Google Scholar 

Konieczna J, Fiol M, Colom A, et al. Does consumption of ultra-processed foods matter for liver health? Prospective analysis among older adults with metabolic syndrome. Nutrients 2022;14(19) https://doi.org/10.3390/nu14194142 [published Online First: 2022/10/15]

Hill C, Guarner F, Reid G, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014;11(8):506–14. https://doi.org/10.1038/nrgastro.2014.66 [published Online First: 2014/06/11]

Wen X, Liu H, Luo X, et al. Supplementation of Lactobacillus plantarum ATCC14917 mitigates non-alcoholic fatty liver disease in high-fat-diet-fed rats. Front Microbiol 2023;14:1146672. https://doi.org/10.3389/fmicb.2023.1146672[publishedOnlineFirst:2023/06/02] .

Article  PubMed  PubMed Central  Google Scholar 

O’Callaghan A, van Sinderen D. Bifidobacteria and their role as members of the human gut microbiota. Front Microbiol 2016;7:925. https://doi.org/10.3389/fmicb.2016.00925[publishedOnlineFirst:2016/07/06] .

Article  PubMed  PubMed Central  Google Scholar 

Lu J, Shataer D, Yan H, et al. Probiotics and non-alcoholic fatty liver disease: unveiling the mechanisms of Lactobacillus plantarum and Bifidobacterium bifidum in modulating lipid metabolism, inflammation, and intestinal barrier integrity. Foods (Basel, Switzerland) 2024;13(18) https://doi.org/10.3390/foods13182992 [published Online First: 2024/09/28 22:45]

Holmberg SM, Feeney RH, Prasoodanan PKV, et al. The gut commensal Blautia maintains colonic mucus function under low-fiber consumption through secretion of short-chain fatty acids. Nat Commun 2024;15(1):3502. https://doi.org/10.1038/s41467-024-47594-w[publishedOnlineFirst:2024/04/26] .

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gibson GR, Hutkins R, Sanders ME, et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017;14(8):491–502. https://doi.org/10.1038/nrgastro.2017.75[publishedOnlineFirst:2017/06/15] .

Article  PubMed  Google Scholar 

Mofidi F, Poustchi H, Yari Z, et al. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial. Br J Nutr. 2017;117(5):662–8. https://doi.org/10.1017/s0007114517000204[publishedOnlineFirst:2017/03/28] .

Article  CAS  PubMed  Google Scholar 

Malaguarnera M, Vacante M, Antic T, et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci. 2012;57(2):545–53. https://doi.org/10.1007/s10620-011-1887-4[publishedOnlineFirst:2011/09/09] .

Article  PubMed  Google Scholar 

Bomhof MR, Parnell JA, Ramay HR, et al. Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial. Eur J Nutr. 2019;58(4):1735–45. https://doi.org/10.1007/s00394-018-1721-2[publishedOnlineFirst:2018/05/21] .

Article  CAS  PubMed  Google Scholar 

Gu YJ, Chen LM, Gu ME, et al. Body mass index-based predictions and personalized clinical strategies for colorectal cancer in the context of PPPM. EPMA J. 2022;13(4):615–32. https://doi.org/10.1007/s13167-022-00306-0. [publishedOnlineFirst:2022/12/13].

Article 

Comments (0)

No login
gif